Oncologist-Reported Reasons for Not Ordering Multimarker Tumor Panels: Results From a Nationally Representative Survey Supported in part by the United States Department of Veterans Affairs, Veterans ...

Two KRAS-targeted strategies are starting to reshape treatment for metastatic pancreatic cancer after decades of limited progress with chemotherapy.

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly ...

Pancreatic ductal adenocarcinoma has a five-year survival rate of roughly 13 percent, according to the American Cancer ...

Q: Should I be tested for the KRAS mutation before beginning colorectal cancer treatment? Recent research confirmed that the mutation status of the KRAS gene in colon cancer patients can determine if ...

Please provide your email address to receive an email when new articles are posted on . Less than half of patients received MSI testing and about one-quarter received KRAS testing. Older age, rural ...

Laboratory Corporation of America Holdings or LabCorp LH recently announced the availability of therascreen KRAS PCR Mutation Analysis -- a companion diagnostic (CDx) to spot patients with non-small ...

Amgen and Mirati Therapeutics may lead the race to develop KRAS inhibitors to treat cancer, but their candidates only target G12C-mutant tumors. Enter Boehringer Ingelheim, which has just advanced its ...

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today presented promising preclinical data from its pan-KRAS program including the novel, oral inhibitor BI 1701963 at the AACR-NCI-EORTC ...